Inventiva S.A. (NASDAQ:IVA) Short Interest Up 34.9% in April

Inventiva S.A. (NASDAQ:IVA) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 77,700 shares, a growth of 34.9% from the March 31st total of 57,600 shares. Based on an average daily volume of 39,500 shares, the days-to-cover ratio is currently 2.0 days.

Analyst Ratings Changes

Several research firms have weighed in on IVA. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Inventiva in a research report on Monday, April 1st. Lifesci Capital reaffirmed an “outperform” rating on shares of Inventiva in a research report on Friday, January 5th. Stifel Nicolaus dropped their price target on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Finally, Canaccord Genuity Group lifted their price objective on shares of Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $17.00.

Inventiva Price Performance

IVA stock traded down $0.06 during trading on Tuesday, hitting $3.18. The company had a trading volume of 2,102 shares, compared to its average volume of 34,210. The company has a fifty day moving average price of $3.63 and a two-hundred day moving average price of $3.89. Inventiva has a fifty-two week low of $2.43 and a fifty-two week high of $5.05.

Hedge Funds Weigh In On Inventiva

A hedge fund recently raised its stake in Inventiva stock. Commonwealth Equity Services LLC lifted its holdings in shares of Inventiva S.A. (NASDAQ:IVA) by 20.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,435 shares of the company’s stock after purchasing an additional 4,155 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Inventiva were worth $103,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.